Australian construction leaders gather in Queensland to address industry issues
McCullough Robertson’s 17th Annual Construction Law Conference, one of the leading construction events in Australia, held in Queensland, will see industry heavyweights discuss and debate the future of the sector.
Despite a recent rebound, it’s been a tough time for the $44bn industry as market conditions deteriorate and proposed reforms create increased uncertainty and division across the sector.
Queensland Building and Construction Commission (QBCC) Commissioner Brett Bassett will shed much-needed light on the industry’s most poignant issues in a panel discussion at the event, to be held on 14 September.
- Digital Realty breaks ground on new Sydney data centre construction
- Construction industry rebounds thanks to commercial project uplift
- Read the latest edition of Business Review Australia magazine
More than 240 builders, engineers, contractors, sub-contractors and project leads from all corners of Queensland and New South Wales are expected at Rydges South Bank for a full run-down on recent and proposed reforms around non-conforming building products, security of payment, licensing, and compliance with workplace health and safety requirements.
Attendees will include representatives from Hutchinson Builders, Downer, FKG, Sandvik, Broadspectrum, Grocon, Department of Transport and Main Roads, Brisbane City Council, Department of Public Works, James Cook University, Sunshine Coast University, Georgiou and Telstra.
Other speakers include McCullough Robertson strategic advisers Michael Roche and Graham Cox who will comment on the state of the resources sector and opportunities on offer in the renewables space.
McCullough Robertson Partner Ren Niemann will comment in response to the constraints on government budgets and the need for priority infrastructure projects to progress.
Saddled with legislative uncertainty, Queensland’s building, construction and engineering sector is still coming to grips with the end of the mining and LNG boom, which delivered a healthy $70bn over six years.
Seo JungJin: Who is EY’s World Entrepreneur of 2021?
Seo JungJin, founder of biopharma firm Celltrion, which most recently developed an antibody treatment for COVID-19, has been named the EY World Entrepreneur of the Year 2021, becoming the first South Korean in the award’s 21-year history.
Regarded as one of the world’s most prestigious business awards program for entrepreneurs, the EY Entrepreneur of the Year celebrates visionary and innovative leaders from across 60 countries who are transforming the world and fostering growth.
JungJin, who is now honoroary chairman of Celltrion Group, was up against a worthy cast of entrepreneurial competitors, taking the crown from among 45 award winners across 38 countries and territories.
Speaking during the virtual event, JungJin described his own interpretation of entrepreneurship as something that brings together “a group of people toward a common vision, embracing challenges as opportunities and committing oneself to contribute to the greater good”.
Why was JungJin crowned King Entrepreneur?
A South Korean native and now 63 years of age, JungJin founded biopharmaceutical firm Celltrion in 2003. In the nearly two decades since its founding, Celltrion has lived up to its goal of advancing health and welfare for all by developing ground-breaking drugs to treat autoimmune disease, various forms of cancer and, most recently, COVID-19.
The company, which JungJin started with just US$45,000 and five of his colleagues, has since growth to more than 2,1000 employees with sales permits in more than 90 countries and revenues exceeding US$1.69bn.
According to the panel, JungJin’s story is a shining example of the power of an unstoppable entrepreneur to change the world with the pandel moved by both his incredible story and his purpose-driven leadership, innovative mindset and entrepreneurial spirit.
Described by the chair of the EY judging panel Rosaleen Blair as “representing everything an unstoppable should be” from taking on the world’s biggest health care challenges to consistently creating long-term value for his company, JungJin’s story is one of incredible tenacity and perseverance that the judging panel felt most represented the entrepreneurial spirit.
“He’s taken breathtaking risks, both personal and professional, to found Celltrion and grow it into one of the world’s leading biopharmaceutical companies,” says Stasia Mitchell, EY Global Entrepreneurship Leader. “His passion for creating affordable, life-saving health care and flair for tackling global problems has led to many treatments that have helped millions of people worldwide and was especially evident this past year through the creation of a COVID-19 antibody treatment.”
How did JungJin get there?
JungJin's entrepreneurial journey started at an early age when he worked as a taxi driver to get himself through Konkuk University in Seoul, South Korea. After studying industrial engineering, he rose through the ranks of Daewoo Motor Co. before losing his job amid the carmaker’s financial troubles following the 1997 Asian economic crisis.
Following this, JungJin started collaborating with colleagues to explore business opportunities in different industries, though none delivered lasting success. The turning point came after he attended a talk hosted by renowned scholars, which inspired him to focus on the biopharmaceutical sector.
And so he founded Celltrion with just US$45,000 of his savings. The launch of Remsima, credited with being the world's first antibody biosimilar, quickly moved Celltrion up the ranks of the country's fairly underdeveloped pharmaceutical sector. Celltrion followed this success with the launch of drugs for breast cancer and lymphoma that today are being used worldwide.
With ambitions to be the world’s first in different areas, Celltrion has pioneered numerous uncharted areas to great success over the past two decades, most recently responding to the global pandemic by successfully developing an antibody treatment for COVID-19 and working to ensure a timely supply of the safe and effective treatment.
“When I first started, my vision was to help patients gain access to safe, effective and affordable medicines and thereby enhance the quality of people’s lives,” explains JungJin. “The success of Celltrion has enabled me to expand on this while finding new ways to fuel my entrepreneurial drive.”